Teva sues CMS over Medicare drug price negotiations

Teva Pharmaceutical Industries’ (NYSE:TEVA) U.S. division has sued CMS over the Medicare drug pricing negotiations policy included in the Inflation Reduction Act.

In its lawsuit filed in D.C. federal court, the Israel-based drugmaker says that guidance CMS has issued on price negotiations “gives